Dazodalibep Meets ESSDAI Primary End Point in Phase 3 Sjögren's TrialByVictoria JohnsonSeptember 22nd 2026
Efgartigimod Sustains Sjögren's Disease Control Through 48 Weeks in RHO+ OLEByIsabelle Peene, MD, PhDJune 26th 2026